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Abstract
1α,25-Dihydroxyvitamin D3 (1α25VitD3) has potent immunomodulatory properties. We have
previously demonstrated that 1α25VitD3 promotes human and murine IL-10-secreting CD4+ T
cells. Because of the clinical relevance of this observation, we characterized these cells further and
investigated their relationship with Foxp3+ regulatory T (Treg) cells. 1α25VitD3 increased the
frequency of both Foxp3+ and IL-10+ CD4+T cells in vitro. However, Foxp3 was increased at high
concentrations of 1α25VitD3 and IL-10 at more moderate levels, with little coexpression of these
molecules. The Foxp3+ and IL-10+ T-cell populations showed comparable suppressive activity.
We demonstrate that the enhancement of Foxp3 expression by 1α25VitD3 is impaired by IL-10.
1α25VitD3 enables the selective expansion of Foxp3+ Treg cells over their Foxp3− T-cell
counterparts. Equally, 1α25VitD3 maintains Foxp3+ expression by sorted populations of human
and murine Treg cells upon in vitro culture. A positive in vivo correlation between vitamin D
status and CD4+Foxp3+ T cells in the airways was observed in a severe pediatric asthma cohort,
supporting the in vitro observations. In summary, we provide evidence that 1α25VitD3 enhances
the frequency of both IL-10+ and Foxp3+ Treg cells. In a translational setting, these data suggest
that 1α25VitD3, over a broad concentration range, will be effective in enhancing the frequency of
Treg cells.
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Introduction
Considerable interest exists in the therapeutic potential of regulatory T (Treg) cells to treat a
range of immune-mediated pathologies in humans. This is partly based on evidence obtained
from animal models of human disease demonstrating the capacity of Treg cells to control
transplant rejection, and to successfully treat autoimmune and allergic disease [1]. Two
broad therapeutic strategies are being considered in research initiatives worldwide: (i)
adoptively transferring Treg cells that have previously been expanded in vitro into patients
and (ii) inducing or boosting endogenous Treg cells directly in patients. The latter approach
may be more applicable in highly prevalent conditions such as allergy and asthma, which
cause considerable morbidity, but are generally not life threatening. The rationale for such a
strategy is further strengthened by evidence that existing therapies for allergic diseases, such
as allergen immunotherapy and glucocorticoids, are associated with the induction of Treg
cells in patients [2]. Nevertheless, considerable scope for improving the safety and efficacy
of these treatments exists.
Recent studies have focused on the capacity of vitamin D to modulate Treg-cell subsets. For
example, culturing dendritic cells (DCs) with the active form of vitamin D, 1α,25-
dihydroxyvitamin D3 (1α25VitD3) leads to impaired DC maturation, development of
tolerogenic properties [3], and the capacity to induce CD4+Foxp3+ cells with suppressive
activity [4], or IL-10 expressing Treg cells [5]. In animal models of human disease,
administration of 1α25VitD3 successfully treats transplant rejection [6] and a range of
autoimmune conditions, including antiretinal autoimmunity [7], acute colitis [8], diabetes
[6], arthritis [9], and EAE [10], as well as allergic airway disease [11]. These studies
demonstrate a correlation between therapeutic efficacy and increased frequency or quantities
of CD4+CD25+ T cells, IL-10, TGF-β, and CTLA-4.
Our earlier studies have highlighted the capacity of 1α25VitD3 to promote human CD4+
IL-10 secreting Treg cells (IL-10-Treg) in culture both alone [12] and in concert with
glucocorticoids such as dexamethasone [13,14]. Furthermore, treatment of severe steroid
refractory asthma patients with 1α25VitD3 in vivo directly increased IL-10 gene expression
in CD3+CD4+ T cells [12], and restored the impaired steroid-induced IL-10 response in
CD4+ cells in vitro [14,15].
The present study was designed to further investigate the mechanisms underlying the
therapeutic potential of 1α25VitD3 in the context of asthmatic disease, and to determine
effects on the induction of both IL-10+ and Foxp3+ T cells. Specifically, we have examined
the effects of 1α25VitD3 on total, unfractionated CD4+ T-cell populations, representative of
those likely to be encountered in vivo. The data demonstrate that 1α25VitD3 increases the
frequency not only of IL-10-Treg cells, but also of Foxp3+ Treg cells, that these cells
express increased levels of the inhibitory receptors CTLA-4 and PD-1, and exhibit inhibitory
function. The data further suggest that 1α25VitD3 functions to maintain Foxp3 expression
in the existing Foxp3+ Treg-cell pool.
Results
1α25VitD3 increases the frequency of both IL-10+ and Foxp3+ human CD4+ T cells in
culture
We have previously described the induction of IL-10 secreting cells following culture of
human CD4+ T cells with 1α25VitD3 in vitro and directly ex vivo following administration
of calcitriol to asthma patients [12,14]. An unusual dose response was observed in vitro with
1α25VitD3 at the very highest concentration tested (10−6 M 1α25VitD3) resulting in
considerably lower IL-10 secretion than the optimal concentrations of 10−7 M and 10−8 M
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1α25VitD3 [12]. Here, we analyzed this dose response further and investigated whether
IL-10 was being synthesized by Foxp3 positive or negative T cells in response to
1α25VitD3 in culture.
Human peripheral blood CD4+ T cells were stimulated with anti-CD3, IL-2, and IL-4 under
conditions previously determined to optimally induce IL-10-Treg cells [12]. The expression
of Foxp3 and IL-10 in the presence or absence of 1α25VitD3 was determined by flow
cytometry. 1α25VitD3 at 10−6 M led to an increase in Foxp3 expression as compared with
control cultures (No VitD3), whereas lower doses of 1α25VitD3 minimally affected Foxp3
expression. In contrast, maximal IL-10 induction was observed, as expected, at 10−7 M and
10−8 M 1α25VitD3 [12]. This response was confirmed using a panel of donors. A
statistically significant increase in the frequency of Foxp3+ T cells was observed at 10−6 M,
but not at 10−7 M 1α25VitD3, while significant induction of IL-10+ T cells was seen at 10−7
M, but not at 10−6 M (Fig. 1A). In summary, 1α25VitD3 enhances both the percentage of
Foxp3+ cells and the expression of Foxp3 transcripts (data not shown), but at a distinct
concentration of 1α25VitD3 than required for optimal IL-10 induction.
In our early studies, cells were analyzed for expression of Foxp3 and IL-10 independently
by flow cytometry. To confirm and extend the finding of differential effects of 1α25VitD3
on these molecules, a protocol for costaining was developed. CD4+ T cells were cultured
with 10−6 M or 10−7 M 1α25VitD3 and then restimulated with anti-CD3 and IL-2 for 16 h
and analyzed for expression of IL-10 and Foxp3 by secretion assay and then intranuclear
staining.
In two representative donors, shown in Figure 1B, virtually no (≤0.2%) cells stained positive
for both Foxp3 and IL-10 in the presence of 10−7 M 1α25VitD3. When cells from a panel of
healthy donors were screened, we observed that cell cultures preferentially expressed a high
frequency of Foxp3+ cells and low levels of IL-10, or conversely low Foxp3 and a high
frequency of IL-10+ cells in response to culture with 1α25VitD3 (Fig. 1B and C).
Since Foxp3 expression may not always reflect inhibitory function, the functional
consequences of 1α25VitD3 modulation of Foxp3 versus IL-10 expression by human CD4+
T cells was next investigated.
1α25VitD3-enhanced IL-10 and Foxp3+ T cells show regulatory function and phenotype
CD4+ T-cell lines generated from the same donor in the presence of either high (10−6 M;
Foxp3-promoting Treg conditions) or lower (10−7 M; IL-10-Treg favoring conditions)
concentrations of 1α25VitD3 were tested for their capacity to inhibit the proliferation of
autologous, naïve CFSE-labeled responder T cells. Both populations showed comparable
inhibitory activity (Fig. 2A). The suppression by cells generated with 10−7 M 1α25VitD3
could be diminished by the addition of anti-IL-10 receptor antibody to the co-culture, while
in T-cell cultures generated with 10−6 M 1α25VitD3, the antibody had little effect (Fig. 2B),
suggesting both IL-10-dependent and IL-10-independent mechanisms of suppression existed
in the two different populations.
To further investigate the phenotype of 1α25VitD3-treated cells, T cells were cultured with
a range of concentrations (10−9–10−6 M) of 1α25VitD3 and analyzed for expression of
surface markers by flow cytometry. A number of Treg-associated molecules, including the
inhibitory molecules PD-1 and CTLA-4, as well as CD38 and CD25 were shown to be
increased following exposure to 1α25VitD3, although the expression of the Treg-associated
marker, GITR, and also CD62L, were inhibited by 1α25VitD3 (Fig. 3).
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The enhancement of Foxp3 expression by 1α25VitD3 is impaired by IL-10
We have previously shown that IL-10 expression is reduced when IL-10 signaling is
neutralized in culture [12,13]. Cells were stimulated in the absence or presence of 10−8 –
10−6 M 1α25VitD3 together with either an anti-IL-10R antibody or the appropriate isotype
control reagent. In a representative donor shown in Fig. 4A, a high frequency of Foxp3+
cells was observed following culture with 10−6 M 1α25VitD3 and the presence of anti-
IL-10R antibody in culture did not alter this. In contrast, considerably less Foxp3+ cells were
detected in cell cultures containing 10−7 M or 10−8 M 1α25VitD3, and the addition of anti-
IL-10R to these cultures resulted in a marked increase in the frequency of Foxp3+ cells (Fig.
4A; mean data from four healthy donors depicted in Fig. 4C). These data were also
replicated at the mRNA level using real time RT-PCR where addition of anti-IL-10R
antibody resulted in a significant increase in Foxp3 transcripts, with a reciprocal decrease in
IL-10 transcripts (Fig. 4B).
To confirm these findings of the effects of IL-10 on 1α25VitD3-enhanced Foxp3
expression, a complimentary approach was used. CD4+ T-cell stimulation cultures were
established with high 10−6 M 1α25VitD3 in the presence or absence of recombinant IL-10.
As predicted, the presence of IL-10 significantly inhibited the frequency of Foxp3+ T cells
compared with 10−6 M 1α25VitD3 alone (Fig. 4D).
TGF-β is required for the peripheral induction of Foxp3, both alone and in conjunction with
retinoic acid (RA) [16–20]. Note in this study, no significant increase in Foxp3 expression
was observed when exogenous TGF-β alone was added to cultures containing 10−6 M or
10−7 M 1α25VitD3 (data not shown). However, neutralization of endogenous TGF-β (by
the addition of an antibody specific for TGF-β to the culture) decreased 1α25VitD3-
enhanced Foxp3 expression (Supporting Information Fig. 1), suggesting a possible role for
TGF-β.
1α25VitD3 maintains the expression of Foxp3+ T cells in culture
Human CD4+CD25high cells, which are largely Foxp3+, are known to lose expression of
Foxp3 over time upon culture in vitro. To determine if 1α25VitD3 acted to maintain the
expression of Foxp3 in this population, CD4+CD25high (>99% CD25+; 86% Foxp3+; Fig.
5A) T cells were isolated by cell sorting and cultured for 7 days with or without 1α25VitD3.
The frequency of Foxp3+ cells diminished from 86 to 11.7% upon culture with anti-CD3 and
low dose IL-2 alone, shown in a representative plot in Figure 5B. In contrast, stimulation of
CD4+CD25high cells in the presence of 10−7 M and 10−6 M 1α25VitD3 resulted in 32% and
63.7% of the cells remaining Foxp3+, respectively, in the representative data shown in Fig.
5B. These data suggest 1α25VitD3 contributes to the retention of Foxp3+ expression by
human CD4+CD25high T cells.
To confirm and extend these data, these experiments were repeated with mouse T cells.
When total unfractionated CD4+ cells (>99% pure) were cultured in the absence or presence
of 1α25VitD3, Foxp3 expression was increased from 3% to 7.3% with 10−7 M 1α25VitD3
in the example shown (Supporting Information Fig. 2A). When purified CD4+Foxp3GFP+
cells (>97% Foxp3+) were stimulated with anti-CD3 and IL-2, in the absence of 1α25VitD3,
Foxp3 expression was greatly reduced following 7 days of culture. In contrast, in cultures
containing 10−7 M and 10−6 M 1α25VitD3, more than 50% of the cells remained Foxp3+
(Supporting Information Fig. 2B?). The addition of RA plus TGF-β to all cell cultures
enhanced Foxp3 expression as predicted from independent published data. Collectively,
these data support the evidence from experiments with human T cells that 1α25VitD3
enhances the frequency of Foxp3+ cells by maintaining Foxp3 expression in culture.
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1α25VitD3 favors the expansion of Foxp3+ over Foxp3− T cells
An enrichment in the percentage of Foxp3+ cells was observed in the presence of 10−6 M
1α25VitD3, or in the presence of lower concentrations of 1α25VitD3 plus anti IL-10R
antibody. As 1α25VitD3 has well-documented inhibitory effects on T-cell cycle and
proliferation, we investigated the capacity of 1α25VitD3 to directly modify the proliferation
of Foxp3+ versus Foxp3− T cells using CellTrace Violet. This highly stable dye enabled
monitoring of cell division of Foxp3+ and Foxp3− cells for up to 14 days of culture by flow
cytometry.
In the absence of 1α25VitD3, comparable proportions of the major Foxp3− and the minor
Foxp3+ T-cell populations had proliferated by day 7 and day 14 of culture. The addition of
1α25VitD3 10−6 M to the culture, impaired both FoxP3− and Foxp3+ T-cell proliferation at
days 7 and 14 (Fig. 6A). However, whereas the Foxp3− T-cell proliferative response was
almost completely abrogated, a clear Foxp3+ T-cell response, albeit reduced, could still be
observed. The difference in the proliferative response between these two populations was
significant (Fig. 6B). The addition of anti-IL-10R into cultures containing 10−7 M
1α25VitD3 resulted in a significant increase in cell division in the Foxp3+, but not the
Foxp3− T cells at day 7 (Supporting Information Fig. 3) and to a lesser extent at day 14 (data
not shown). Together these data suggest that a contributory mechanism by which
1α25VitD3 increases the frequency of Foxp3+ cells is via the preferential inhibition of the
proliferation of Foxp3− cells.
In order to distinguish between effects of 1α25VitD3 on existing Treg cells compared with
newly generated adaptive and/or activation-dependent Foxp3 expression arising from the
effector population, Treg (CD4+CD25highCD127low) and T-effector
(CD4+CD25−CD127high) cells were isolated from the same donor to high purity (Supporting
Information Fig. 4). The two populations were individually labeled with CellTrace and then
co-cultured at the original ratio (one Treg to nine effector cells), combining either labeled
Treg with unlabeled T-effector cells, or conversely labeled T-effector cells with unlabeled
Treg cells. These experiments demonstrate that a very low frequency of Foxp3+ T cells arise
from the labeled effector T-cell population, cultured alone or with labeled Treg cells, in the
absence or presence of 1α25VitD3 (<2% at day 14; data not shown). These data suggest that
1α25VitD3 is not acting to enhance adaptive/activation-dependent Foxp3 expression.
Furthermore, across a dose titration of 1α25VitD3, Treg cell proliferation was only reduced
at 10−6 M 1α25VitD3, whereas at all other concentrations proliferation was unaffected or
even enhanced (Fig. 6C and D). In contrast, proliferation of labeled effector T cells in co-
culture was reduced at all concentrations of 1α25VitD3 tested (10−9–10−6 M 1α25VitD3;
Fig. 6C and D). These data imply that culture of T cells with 1α25VitD3 preferentially
expands Treg over T-effector cells.
Evidence for a role of 1α25VitD3 in the maintenance of Foxp3+ T-cell frequencies in vivo
Our earlier studies demonstrated that 1α25VitD3 enhances IL-10 expression by CD4+ T
cells not only in culture, but also following ingestion of standard formulary doses of
1α25VitD3 by both steroid refractory asthma patients and healthy subjects [12,14].
Subsequent work has demonstrated that no parallel increase in Foxp3 gene expression
occurred in the same peripheral blood CD3+CD4+ T cells, analyzed directly ex vivo pre- and
post-1α25VitD3 ingestion (data not shown). To investigate whether vitamin D might
influence Foxp3 expression in the tissues, we analyzed the frequency of CD4+Foxp3+ cells
in bronchoalveolar lavage (BAL) samples available from a pediatric severe asthma cohort
under study, where serum 25-hydroxyvitamin D3 status was also being assessed (Supporting
Information Table 1) [21]. Strikingly the majority of these patients showed a vitamin D
status reflecting insufficiency (<75nmol/L) or deficiency (<50 nmol/L) [22]. A statistically
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significant correlation between serum vitamin D status, and the frequency of CD4+Foxp3+ T
cells in the BAL was observed (r = 0.71, p = 0.02), suggesting an in vivo correlate of our in
vitro observations on the capacity of 1α25VitD3 to influence Foxp3+ Treg cell prevalence
(Fig. 7 and Supporting Information Fig. 5).
Discussion
Interest in enhancing Treg cells in patients is clearly driven by the therapeutic potential of
these cells. An attractive approach would be the use of pharmacological agents such as
1α25VitD3, or vitamin D supplementation, to induce the expansion and/or maintenance of
Treg cells. This approach is especially suited to ongoing chronic diseases such as asthma
that occur at high prevalence, where a simple treatment such as vitamin D supplementation
would be relatively safe, acceptable to patients, and cost effective. The present study aimed
to investigate the capacity of 1α25VitD3 to promote Treg cells and whether dose-dependent
limitations exist.
Early indications from clinical studies suggest vitamin D treatment of patients enhances T-
cell expression of IL-10 in vivo, although data on the impact on Foxp3+ Treg cell
frequencies in human peripheral blood are less clear [12,23–26]. Here, we demonstrate that
the active form of vitamin D3 increases the frequency of both IL-10+ and Foxp3+ cells in
cultures of human peripheral blood derived CD4+ T cells. The two Treg cell subsets
promoted by 1α25VitD3 are distinct cell populations that are optimally induced by different
concentrations of 1α25VitD3 in culture.
Both Foxp3+ and IL-10+ 1α25VitD3-promoted T cells exhibited comparable regulatory
activity in a conventional in vitro suppression assay. However, more than one inhibitory
mechanism appears to exist. Inhibition by T cells generated under conditions that optimally
promoted IL-10 was reversed upon addition of an antibody that blocked IL-10 signaling to
the co-culture suppression assay. In contrast, the suppressive activity of Foxp3+ cells,
generated in the presence of high-dose 1α25VitD3, was not reversed by neutralization of
IL-10. A number of additional mechanisms of suppression by Foxp3+ Treg cells have been
reported [27].
To investigate how vitamin D modulates the frequency of Foxp3+ cells in culture, initial
studies focused on the capacity of 1α25VitD3 to maintain expression of Foxp3 by existing
Treg cells. 1α25VitD3 maintained the levels of Foxp3 expression in human CD4+CD25high
Treg cells, which otherwise were lost upon in vitro culture. This observation was reproduced
using Foxp3GFP CD4+ cells from reporter mice. Using the CellTrace together with Foxp3
staining, we further demonstrated that 1α25VitD3 allowed the preferential expansion of
Foxp3+ T cells over Foxp3− (effector) T cells and this could provide a contributory or
additional mechanism by which 1α25VitD3 promotes Foxp3+ Treg cells. These data,
together with earlier studies suggesting that vitamin D increases Foxp3 expression in human
naïve T-cell cultures [10,28], indicate that vitamin D acts through several different
mechanisms to enhance Foxp3 expression. IL-2 plays a central role in the maintenance of a
functional Treg cell compartment [29,30]. Interestingly, our data suggest that one
mechanism by which 1α25VitD3 may act to maintain Treg cells is via the observed
increased expression of the alpha chain of the IL-2 receptor, CD25, and this could be
relevant to all of the pathways proposed above.
An unprecedented finding of the present study is the reciprocal regulation of Foxp3 and
IL-10 by 1α25VitD3. The phenotype of the Treg cell population generated is likely to
depend not only upon the level of vitamin D available, but also the local cytokine milieu. In
addition to the well-documented requirement for IL-2 to maintain Treg homeostasis, we
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envisage that in the presence of higher concentrations of IL-10, IL-10-Treg induction will be
favored. Conversely, elevated TGF-β and reduced IL-10 in 1α25VitD3-driven cultures will
result in Foxp3+ Treg cell generation. Our observations that exogenous IL-10 in
1α25VitD3-driven cultures reduces the frequency of Foxp3+ T cells, while blocking IL-10
signaling in these cultures increases Foxp3+ T-cell frequency, further indicate reciprocity in
control of IL-10 and Foxp3 expression. We show that Foxp3 expression was significantly
enhanced by 1α25VitD3 following 14 days of culture (as previously reported for IL-10
[12]), while enhancement at day 7 was variable and did not achieve statistical significance
(data not shown). This may indicate that longer-term exposure to vitamin D, arguably
reflecting the situation in a vitamin D replete individual, will favor Treg cells in patients.
A high prevalence of vitamin D insufficiency has been documented in asthma cohorts
worldwide. A strong association between low vitamin D status with severity and poor
control of asthma has been shown by several independent groups of investigators [31–36].
Our own studies have addressed this in a severe therapy-resistant pediatric asthma cohort.
We observe highly significant associations between serum 25-hydroxyvitamin D3 levels
with lung function, asthma severity, and control [21]. Using this unique patient cohort, we
recorded a positive correlation between serum 25-hydroxyvitamin D3 levels with the
frequency of CD25+Foxp3+ T cells in the airways, complimenting our in vitro observations.
Additionally, we have very recently observed that the frequency of CD4+CD127lowFoxp3+
T cells in the periphery of steroid sensitive is higher than in steroid refractory adult moderate
to severe asthmatics, and go on to demonstrate a significant correlation between serum
vitamin D status and the number of these cells in the periphery [37]. Together, these
association data support the concept that vitamin D status may control Foxp3+Treg
frequencies in vivo, which could represent a mechanism whereby vitamin D treatment
dampens asthma symptoms. However, two recently published studies using either a
hypocalcaemic vitamin D analogue [24] or high-dose vitamin D supplementation in patients
with multiple sclerosis [23] showed no increase in the frequency of peripheral blood
CD4+Foxp3+ T cells following vitamin D treatment. Clearly further translational studies in
patients are required to fully understand the impact of vitamin D on Treg cells in humans.
Although these studies were designed to investigate a role for vitamin D in a therapeutic
context, they also have implications regarding a physiological role for vitamin D in immune
modulation, including Treg frequency as highlighted by the data from pediatric BAL.
Extrarenal synthesis of active vitamin D is increasingly being recognized as important for
modulation of both innate and adaptive immunity [38]. Vitamin D3 can be metabolized into
1α25VitD3 by a variety of immune and structural cells including DCs [38,39], macrophages
[40], and epithelial cells [41], which is proposed to result in relatively high 1α25VitD3
concentrated locally in the lymphoid microenvironment for presentation to interacting T-
cells [42]. Thus, local synthesis of 1α25VitD3 in tissues may influence Treg frequency,
although what constitutes “physiological” levels of 1α25VitD3 generated locally in tissues,
and how these reflect observations from in vitro studies is as yet difficult to ascertain.
Production of 1 × 10−9–6 × 10−8 M 1α25VitD3 by antigen presenting cells has been
reported [39,42], which is not that dissimilar to what is used in the present study.
In summary, vitamin D deficiency and insufficiency is increasing being associated with a
wide range of immune-mediated pathologies [22,43]. In a translational setting, these data
suggest that 1α25VitD3, over a broad concentration range, is likely to be safe and effective
in enhancing the frequency of both Foxp3+ and IL-10+ Treg cell populations in patients. We
believe, supported by our data and others, that vitamin D delivered either through
supplementation or pharmacologically, including novel derivatives that lack the side effect
of hypercalcaemia, could prove candidates for increasing the frequency of Treg cell
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populations in patients. This type of approach may be particularly amenable in patients
where individually tailored therapies are impractical.
Materials and methods
Mice
Wild-type C57BL/6 and genetically modified Foxp3GFP C57BL/6 [44] and TCR transgenic
(TCR7) mice on a Rag1–/– background specific for hen egg lysozyme [45] crossed to
Foxp3GFP C57BL/6 (Foxp3GFP TCR7 Rag1−/−) mice [46] were bred and maintained under
specific pathogen-free conditions at NIMR according to the Home Office UK Animals
(Scientific Procedures) Act 1986 and used at 8–12 weeks of age.
Human studies
PBMCs were obtained from normal healthy individuals in the majority of experiments. The
Ethics Committee at Guy’s Hospital approved the study and all donors provided informed
consent.
Twelve pediatric patients with severe therapy-resistant asthma were also studied (Supporting
Information Table 1). Severe therapy-resistant asthma was defined as persistent chronic
symptoms of airway obstruction, despite treatment with high-dose inhaled corticosteroids
and trials of add on drugs, and/or recurrent severe asthma exacerbations. All children had
been through a detailed protocol to optimize adherence and other aspects of basic
management, as far as possible [21,47]. Bronchoscopies in the pediatric subjects were
performed as previously described [48]. The Royal Brompton Hospital Ethics Committee
approved the study; written age-appropriate informed consent was obtained from parents
and children. Serum 25-hydroxyvitamin D was measured using a two-dimensional high
performance liquid chromatography system–tandem mass spectrometry.
Cell purification and culture
Human PBMCs were isolated as previously described [12]. CD4+ T cells were purified by
positive selection using Dynabeads (Invitrogen; typical purity 98.5%) or cell sorting (typical
purity 99.5%) using a FACSARIA flow cytometer (Becton Dickinson). CD4+CD25high
(purity >99%) cells were isolated by cell sorting from Buffy coats from the National Blood
Service. Treg (CD4+CD25highCD127low; typical purity >98%) and effector T cells
(CD4+CD25-CD127+; purity >99%) were cell sorted from cones obtained from the National
Blood Service.
Human CD4+ T cells (1 × 106 cells/mL) were stimulated with plate-bound anti-CD3 (1 μg/
mL; OKT-3) in RPMI containing 50 U/mL recombinant hIL-2 (Eurocetus), 10 ng/mL hIL-4
(NBS), and calcitriol (1α25VitD3; BIOMOL Research Labs) as indicated, for 7 day cycles.
In some experiments, 5 ng/mL IL-10 (R&D), 5 μg/mL anti-TGF-β (clone 1D11; R&D), 5
μg/mL anti-IL-10R (clone 3F9-2; BD-Pharmingen), or the appropriate isotype control
antibody were added, as indicated. Note cells used for proliferation analysis were stained at
day 0 with 5 mM CellTraceTM Violet (Invitrogen), according to manufacturers’ instructions.
Murine CD4+ T cells were FACS sorted on a MoFlo cytometer (Beckman Coulter) for
CD4+ (purity >99%), CD4+CD44lowCD25− (Foxp3GFP−; purity >99%), or
CD4+Foxp3GFP+ (purity >97%) from CD4-enriched spleen cells. Cells were stimulated in
flat-bottom 96-well plates (0.25 × 106 cells/mL) with plate-bound anti-CD3 (145-2C11) at
2.5 mg/mL in cRPMI medium [45] containing 5 ng/mL recombinant mIL-2 (Insight
Biotechnology) for 7 days. Cells were fed with IL-2 on day 3. Where indicated, 1α25VitD3,
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5 ng/mL recombinant hTGF-b1 (Insight Biotechnology), and 10 nM all trans RA (Sigma-
Aldrich) were added to T-cell cultures.
Functional assays of regulatory function
CD4+ T-cell lines were generated as described above. CD4+CD45RA+ naïve T cells were
labeled with 2 μM CFSE (Molecular Probes, Eugene) and co-cultured with the autologous
line at the ratios indicated, with 0.1 μg/mL plate-bound anti-CD3 and 1 μg/mL anti-CD28
(clone 15E8; Sanquin). In some experiments, anti-IL-10R or IgG control was added to the
co-culture. On day 5, cells were stained with propidium iodide (PI; Sigma-Aldrich) for dead
cell exclusion and 30,000 CFSE positive viable responder cells were acquired on a
FACSCaliber flow cytometer (Becton Dickinson).
Analysis of IL-10 and Foxp3 expression by flow cytometry
Human IL-10+ cells were identified using a commercially available IL-10 Secretion Assay
Detection Kit (Miltenyi Biotec). Foxp3 (clone PCH101) expression was determined by cell
staining using the Foxp3 staining buffer set from Ebiosciences. Quadrant markers were set
according to the matched isotype control antibody staining. Antibodies used for cell surface
phenotyping (BD Biosciences) were PD-1 (clone MIH4), CTLA-4 (clone BN13), CD62L
(clone DREG-56), CD25 (clone M-A251), GITR (clone 110416), and CD38 (clone HIT2).
Expression of Foxp3 in murine CD4+ T cells was determined by excluding dead cells with
LIVE/DEAD Fixable Red Dead Cell Staining Kit (Invitrogen) and intracellular staining for
Foxp3 with staining buffer set from eBiosciences. Samples were acquired on LSR II (BD)
flow cytometer.
Real time PCR
RNA was extracted from cell pellets using RNeasy Mini kit (Qiagen). RNA was reverse
transcribed using random hexamer primers (Fermantas Life Sciences). Real time (RT) PCR
was performed in triplicate using FAM-labeled Assay-on-Demand reagent sets for IL-10
(Hs00174086 m1) and Foxp3 (Hs00203958 m1). RT-PCR reactions were multiplexed using
VIC-labeled 18S primers and probes (Hs99999901 s1) as an endogenous control and
analyzed using SDS software version 2.1 (Applied Biosystems), according to the 2−(ΔΔCt)
method.
Statistics
Results are presented as mean ± SEM, unless indicated. Data were assessed for normality
and equal variation after which the appropriate parametric or nonparametric test was
performed (see individual figure legends). Differences were considered significant at the
95% confidence level. Correlations were verified with the Pearson’s correlation test or the
Spearman’s rank correlation coefficient, as indicated in the figure legend.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1.
1α25VitD3 increases the frequency of IL-10+ and Foxp3+ human CD4+ T cells. Human
CD4+ T cells were stimulated for two 7-day cycles with anti-CD3, IL-2, and IL-4 (No
VitD3) or additionally with the indicated concentration of 1α25VitD3 (VitD3; 10× M). (A)
At day 14, cells were restimulated for 16 h with anti-CD3 and IL-2. IL-10+ cells were
identified using an IL-10 secretion assay kit. FoxP3+ cells were assessed by intranuclear
staining. Values represent the percentage of gated live CD4+ cells. Each symbol represents
an individual donor and lines represent the mean. *p < 0.05 as determined by the Mann–
Whitney rank sum test. (B) Cells were costained for expression of both IL-10 and FoxP3 in
the presence of 10−7 M 1α25VitD3. Two representative flow cytometry plots from different
donors are shown. Note the absence of FoxP3+IL-10+ cells. Data are representative of seven
independent experiments. (C) Data from the costaining experiments are depicted in a
correlation analysis. R2 value was determined by Spearman’s rank correlation coefficient.
Each symbol represents a different donor (n = 8); closed symbols = 10−6 M 1α25VitD3,
open symbols = 10−7 M 1α25VitD3.
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Figure 2.
1α25VitD3-treated CD4+ T-cell populations acquire suppressive properties. (A) Autologous
CD45RA+ T cells were isolated, CFSE-labeled, and co-cultured with the cell lines (No
VitD3 or VitD3, as indicated) at a ratio of 2:1 responder to cell line, for 5 days with anti-
CD3 and CD28. The percentage of proliferating, viable CFSE-labeled responders is shown,
as assessed by flow cytometry. Data are shown as mean ± SEM from four independent
experiments from different healthy donors. *p < 0.05 as determined by the Mann–Whitney
rank sum test. (B) CFSE-labeled ± responder cells were co-cultured with cell lines — (i)
VitD3 10−6M T cells, (ii) VitD3 10−7M T cells–at the ratios indicated in the graph, in the
presence of control IgG (closed symbols) or anti-IL-10R (hollow symbols); both at 5 μg/
mL. Data are representative of four independent experiments.
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Figure 3.
1α25VitD3 promotes the expression of Treg-cell-associated surface markers. Human CD4+
T cells were stimulated alone (No VitD3) or additionally in the presence of the indicated
molar concentrations of 1α25VitD3 (VitD3). At day 14, cells were stained and analyzed for
the surface expression of CD25, CD38, PD-1, CTLA-4, CD62L, and GITR (black lines;
gray lines = matched isotype control) by flow cytometry. For PD-1 and CTLA-4, values
represent percentage of positive cells; all other antigens values shown are indicative of the
geometric mean fluorescence intensity. Data are representative of a minimum of six
independent experiments.
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Figure 4.
The enhancement of Foxp3 expression by 1α25VitD3 is impaired by IL-10.Human CD4+ T
cells were cultured for two 7 day cycles with anti-CD3, IL-2, and IL-4 (No VitD3) or
additionally with the indicated concentration of 1α25VitD3 (VitD3; 10× M) in the presence
of IL-10, anti-IL-10R, or control IgG, as indicated. (A) At day 14, cells were re-stimulated
for 16 h with anti-CD3 and IL-2. IL-10+ cells were determined using a commercially
available IL-10 secretion assay and subsequently stained for intranuclear expression of
Foxp3. Values represent the percentage of gated live cells. (B) Foxp3 and IL-10 gene
expression, as determined by real time RT-PCR. Data are shown normalized to an
endogenous control (18s rRNA) and expressed relative to IgG control-treated cells. Data are
shown as mean +SEM from four independent experiments from different healthy donors.
(C) CD4+ T cells were cultured with a concentration of 10−7 M 1α25VitD3 (VitD3) in the
presence of control IgG or anti-IL-10R. Foxp3 expression was determined by intranuclear
staining for Foxp3. (D) CD4+ T cells were cultured with a concentration of 10−6 M
1α25VitD3 (VitD3) in the presence or absence of IL-10. Foxp3 expression was determined
by intranuclear staining for Foxp3. (C and D) Data are shown as mean +SEM of four
experiments each performed with an individual donor. *p < 0.05 as determined by the
Mann–Whitney rank sum test.
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Figure 5.
Human CD4+CD25+ T cells retain Foxp3 expression in the presence of 1α25VitD3. (A)
Human CD4+CD25high Treg cells were sorted from CD4+ T cells by flow cytometry. Foxp3
expression is depicted in the overlay histogram on the right.(B) Sorted CD4+CD25+ cells
were cultured with anti-CD3 and IL-2 (50 U/mL) in the absence (No VitD3) or the presence
of 10−7 M or 10−6 M 1α25VitD3 (VitD3) as indicated for 7 days and then assessed for
expression of CD25 and Foxp3 by flow cytometry. Data are representative of three
independent experiments each performed with a different healthy donor.
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Figure 6.
1α25VitD3 favors the proliferation of Foxp3+ over Foxp3- T cells.(A) Human CD4+ T cells
were labeled with CellTraceTM Violet and then cultured for one or two 7-day cycles with
anti-CD3, IL-2 (No VitD3), or additionally with the indicated concentration of 1α25VitD3
(VitD3; 10× M). At day 7 and 14, cells were stained for Foxp3 and analyzed by flow
cytometry. Proliferation was assessed by loss of expression of CellTrace with each cell
division. (B) (i) Representative histograms showing CellTrace expression in Foxp3− (filled
histogram) and Foxp3+ (open histogram) T cells at day 14. Note the peaks represent
successive generations of cells. (ii) Data from day 7 (n = 7) and day 14 (n = 4) of the
percentage of original population divided are shown as mean ± SEM of the indicated
number of experiments. *p < 0.05 as determined by the Mann–Whitney rank sum test. (C)
Overlay histograms from a representative donor showing CellTrace expression in
individually labeled Treg or T-effector populations that were then co-cultured with the
nonlabeled population for 14 days at the original ratio of 1:9 in the absence or presence of
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1α25VitD3 as indicated. Filled histograms show proliferation of labeled Treg cells that were
co-cultured with unlabeled T-effector cells. Open histograms assess proliferation of labeled
T-effector cells, co-cultured with unlabelled Treg cells. (D) Data from (C) presented as
percentage of original population divided. Representative data from three independent
experiments each performed with different donors are shown.
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Figure 7.
Serum 25-hydroxyvitamin D3 correlates with the frequency of CD4+ FoxP3+ cells in BAL
of pediatric asthma patients. Pediatric patients with severe therapy resistant asthma (STRA)
were analyzed for the presence of Treg cells (percentage of CD4+ cells expressing Foxp3) in
bronchoaveolar lavage fluid. Serum was collected from the same patients and the
concentration of the circulating form of vitamin D3, 25-hydroxyvitamin D3 was assessed by
two-dimensional high performance liquid chromatography system–tandem mass
spectrometry. Each point represents an individual patient from 11 experiments
performed.The r and p values were assessed using Pearson’s correlation test.
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